Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Decreases By 30.8%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 864,500 shares, a drop of 30.8% from the August 31st total of 1,250,000 shares. Currently, 9.4% of the shares of the company are sold short. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 0.4 days. Currently, 9.4% of the shares of the company are sold short.

Marker Therapeutics Trading Down 1.9%

Shares of MRKR opened at $1.06 on Wednesday. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $5.95. The stock’s 50 day moving average is $1.05 and its two-hundred day moving average is $1.25. The firm has a market cap of $13.72 million, a P/E ratio of -0.77 and a beta of 1.47.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.26. Marker Therapeutics had a negative return on equity of 114.59% and a negative net margin of 271.12%.The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.72 million. Equities research analysts forecast that Marker Therapeutics will post -0.65 EPS for the current year.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Millennium Management LLC acquired a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,108 shares of the company’s stock, valued at approximately $50,000. Millennium Management LLC owned 0.15% of Marker Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen raised Marker Therapeutics to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Marker Therapeutics has an average rating of “Buy” and an average target price of $13.17.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.